SCHEMBL18170637

SCHEMBL18170637

Cc1ccc(-c2ccc(NC(=O)c3ccccc3)c3c2CNC3=O)cc1C

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 13/20 0.68
ROCK2 O75116 2/20 0.48
RET P07949 2/20 0.48
AURKB Q96GD4 2/20 0.48
FLT1 P17948 1/20 0.48
EPHA2 P29317 1/20 0.48
AXL P30530 1/20 0.48
FLT4 P35916 1/20 0.48
FLT3 P36888 1/20 0.48
FRK P42685 1/20 0.48
MAP4K4 O95819 1/20 0.47
LCK P06239 1/20 0.47
PIM1 P11309 1/20 0.47
RPS6KB1 P23443 1/20 0.47
GSK3B P49841 1/20 0.47
BLK P51451 1/20 0.47
PRKCD Q05655 1/20 0.47
PRKAA1 Q13131 1/20 0.47
STK3 Q13188 1/20 0.47
ROCK1 Q13464 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18170968 0.89 KDR (0.63) KDRROCK2RETAURKBFLT1
SCHEMBL18170853 0.88 KDR (0.75) KDRROCK2RETAURKBFLT1
SCHEMBL18171021 0.88 KDR (0.75) KDRROCK2RETAURKBFLT1
SCHEMBL18170622 0.87 KDR (0.71) KDRROCK2RETAURKBFLT1
SCHEMBL18171025 0.86 KDR (0.69) KDRAURKBKMT2ACYP1A2CASP3
SCHEMBL18170971 0.86 KDR (0.64) KDRKMT2ACYP1A2MAPTCYP2C9
SCHEMBL18170742 0.85 KDR (0.59) KDRNPC1RAB9AKMT2ACYP1A2
SCHEMBL18170934 0.85 KDR (0.68) KDRROCK2RETAURKBFLT1
SCHEMBL18170672 0.85 KDR (0.63) KDRROCK2RETAURKBFLT1
SCHEMBL18170609 0.85 KDR (0.63) KDRROCK2RETAURKBFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9856216-B2 Compounds as TNIK, IKKε and TBK1 inhibitors and pharmaceutical composition comprising same GREEN CROSS CORPORATION (KR) 2018-01-02 US claimed
US-20160311772-A1 COMPOUNDS AS TNIK, IKKEPSILON AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME GREEN CROSS CORPORATION (KR) 2016-10-27 US claimed
US-9856216-B2 Compounds as TNIK, IKKε and TBK1 inhibitors and pharmaceutical composition comprising same GREEN CROSS CORPORATION (KR) 2018-01-02 US disclosed
US-9856216-B2 Compounds as TNIK, IKKε and TBK1 inhibitors and pharmaceutical composition comprising same GREEN CROSS CORPORATION (KR) 2018-01-02 US disclosed
US-20160311772-A1 COMPOUNDS AS TNIK, IKKEPSILON AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME GREEN CROSS CORPORATION (KR) 2016-10-27 US disclosed
US-20160311772-A1 COMPOUNDS AS TNIK, IKKEPSILON AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME GREEN CROSS CORPORATION (KR) 2016-10-27 US disclosed
US-20160311772-A1 COMPOUNDS AS TNIK, IKKEPSILON AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME GREEN CROSS CORPORATION (KR) 2016-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160311772-A1 COMPOUNDS AS TNIK, IKKEPSILON AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME TNIK, TNK1, NFKBIA KDR 1662/4885ROCK2 202/4885RET 1030/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.